Mammadli et al., 2020 - Google Patents
Inhibition of ITK differentiates GVT and GVHD in allo-HSCTMammadli et al., 2020
View PDF- Document ID
- 15645465651076641436
- Author
- Mammadli M
- Huang W
- Harris R
- Sultana A
- Cheng Y
- Tong W
- Pu J
- Gentile T
- Henty-Ridilla J
- Dsouza S
- Yang Q
- August A
- Bah A
- Karimi M
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
Allogeneic hematopoietic stem cell transplantation is a life-saving treatment for many malignant and nonmalignant diseases. Donor T cells contained within the graft prevent tumor recurrence via graft-versus-tumor (GVT) effects, however, also cause graft-versus-host …
- 206010018651 Graft versus host disease 0 title abstract description 169
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niogret et al. | Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy | |
| Zhu et al. | Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer | |
| Schaafsma et al. | VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance | |
| Mammadli et al. | Targeting interleukin-2-inducible T-cell kinase (ITK) differentiates GVL and GVHD in allo-HSCT | |
| Kurkó et al. | Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow | |
| Whiteside et al. | Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion | |
| Xu et al. | NFAT1 and NFAT2 differentially regulate CTL differentiation upon acute viral infection | |
| US20240043809A1 (en) | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | |
| WO2014055413A2 (en) | A method of providing cellular therapy using modified natural killer cells or t lymphocytes | |
| Monlish et al. | Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells | |
| Lui et al. | A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation | |
| Mammadli et al. | Targeting SLP76: ITK interaction separates GVHD from GVL in allo-HSCT | |
| Harris et al. | TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses | |
| Cornforth et al. | Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs | |
| US20140294793A1 (en) | Gpr15-mediated homing and uses thereof | |
| Mammadli et al. | Inhibition of ITK differentiates GVT and GVHD in allo-HSCT | |
| Sun et al. | Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor | |
| Haydar et al. | CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity | |
| Bah | Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL | |
| Ham et al. | Single-cell RNA sequencing reveals Immune Education promotes T cell survival in mice subjected to the cecal ligation and puncture sepsis model | |
| US20230141417A1 (en) | Methods and compositions for inactivating interleukin-2-inducible t-cell kinase (itk) | |
| Jin et al. | One infusion of engineered long-lasting and multifunctional T cells cures asthma in mice | |
| Turcinov | The T cell phenotype and receptor repertoire in different stages of rheumatoid arthritis: an immunological timeline | |
| Huang et al. | Targeting SLP76: ITK interaction separates GVHD from GVL in allo-HSCT | |
| Siwicki | Myeloid cells in systemic immune reactions during cancer |